Table 3.
Factors Associated With the Number of Vertebral Fractures (NVFs) in the Rebound Period After Denosumab Discontinuation
| Variate | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| IRR | p Value | IRR | p Value | |
| At denosumab initiation (period 1) | ||||
| Age (years) | 0.99 | 0.49 | ||
| Body mass index (kg/m2) | 1.01 | 0.84 | ||
| Weight (kg) | 1.02 | 0.35 | ||
| Breast cancer | 1.35 | 0.45 | ||
| Parental hip fracture | 1.84 | 0.16 | ||
| T‐score BMD lumbar spine | 0.87 | 0.49 | ||
| T‐score BMD total hip | 0.75 | 0.23 | ||
| T‐score BMD femoral neck | 0.87 | 0.52 | ||
| Bone resorption markers a | 2.41 | 0.23 | ||
| Previous vertebral fracture | 1.46 | 0.31 | ||
| Previous non‐vertebral fracture | 1.008 | 0.98 | ||
| Previous bisphosphonate Tx | 0.25 | <0.0001 | 0.34 | 0.004 |
| During denosumab treatment (period 2) | ||||
| No. of denosumab doses | 1.002 | 0.96 | ||
| Duration of denosumab Tx | 1.002 | 0.79 | ||
| Vertebral fractures | 0.41 | 0.43 | ||
| Non‐vertebral fractures | 0.73 | 0.73 | ||
| T‐score BMD lumbar spine | 0.96 | 0.86 | ||
| T‐score change period 2–1 | 1.19 | 0.73 | ||
| T‐score BMD total hip | 0.52 | 0.009 | 0.46 | 0.001 |
| T‐score change period 2–1 | 0.39 | 1.19 | ||
| T‐score BMD femoral neck | 0.84 | 0.48 | ||
| T‐score change period 2–1 | 0.96 | 0.95 | ||
| After denosumab treatment (period 3) | ||||
| T‐score BMD lumbar spine | 0.78 | 0.14 | ||
| T‐score BMD total hip | 1.71 | 0.28 | ||
| T‐score BMD femoral neck | 0.64 | 0.04 | ||
| Bone resorption markers a | 2.01 | 0.001 | ||
| Non‐vertebral fractures | 4.19 | 0.14 | ||
| Bisphosphonates after denosumab | 0.09 | <0.0001 | 0.08 | <0.0001 |
IRR = incidence rate ratio; BMD = bone mineral density; Tx = treatment.
Negative binomial regression model analysis.
a
Bone resorption markers are indicated in % of the upper premenopausal normal limit of the given method.